Item 5.02 Departure of Directors or Certain Officers; Election of Directors;


          Appointment of Certain Officers; Compensatory Arrangements with Certain
          Officers.

On November 4, 2021, Fred Weiss informed the board of Directors (the "Board") of Osmotica Pharmaceuticals plc that he would retire as a director, with such retirement effective as of November 4, 2021.

On November 4, 2021, the Board approved an amendment to the employment agreement between RVL Pharmaceuticals, Inc. ("RVL") and Brian Markison, dated as of December 3, 2015 (the "Employment Agreement"). Pursuant to this amendment, effective as of November 5, 2021, Mr. Markison will receive a base salary of $525,000, subject to discretionary increases, and will be eligible to receive an annual cash bonus with a target annual bonus equal to 60% of his annual base salary.

The foregoing description of the Employment Agreement does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of the Employment Agreement, a copy of which is filed as Exhibit 10.1 hereto and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.






(d) Exhibits.



Exhibit No.                                 Description
  10.1*         Amendment to Employment Agreement, by and between RVL and Brian
              Markison, dated November 5, 2021
104           Cover Page Interactive Data File (formatted as Inline XBRL)

* Indicates management contract or compensatory plan

© Edgar Online, source Glimpses